NCT Research

Clinical Cancer Research Program in Pancreatic Cancer

Expertise

The HUMS surgical department is one of the largest pancreatic cancer centers in the world (718 pancreatic resections in 2012). Core research areas of the program include surgery (Diener Lancet 2011) adjuvant therapy (Neoptolemos JAMA 2010; Schmidt JCO 2012; Neoptolemos JAMA 2012) and molecular disease mechanisms (Rausch Cancer Research 2010). The BMBF-funded PANC-STRAT consortium aims to decipher mechanisms of pancreatic cancerogenesis and develop individualized early clinical trials. Innovative immunotherapy is developed by the K.H. Bauer Professorship (R. Offringa), the Department of Surgery (Schmitz-Winnenthal, Niethammer BMC Cancer 2012), and NCT Medical Oncology (Halama, Jäger; Gnjatic PNAS 2010). The role of heavy ion therapy will be analyzed in the Prometheus trial (Combs BMC Cancer 2013).

CCRP Pancreatic Cancer
 

Scientific Goals

  • Stratification of surgical, adjuvant, and systemic therapy (PANC-STRAT-Consortium).
  • Understand the role of the immune system and develop immunotherapy.
  • Development of radiotherapy, including heavy ion therapy.
  • Targeting of clonal dynamics in human pancreatic cancer.

  1. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073-81.
  2. Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jäger D. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010; 16;107(11):5088-93.
  3. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov AV, Herr I. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010 Jun 15;70(12):5004-13.
  4. Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein  J, Mansmann U, Jäger D, Capussotti L, Kunz R, Büchler MW. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012; 30(33):4077-83.
  5. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R,  Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012; 308(2):147-56.